• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Novo Nordisk

Phoenix and Raven launch direct-to-patient generic semaglutide after Health Canada approval

By Pallavi Madhiraju on May 21, 2026   Pharma & Biotech  

Phoenix and Raven launch direct-to-patient generic semaglutide after Health Canada approval

Generic semaglutide is cheaper, but access is now the real battleground. Phoenix and Raven are testing Canada’s GLP-1 telehealth future.

Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?

By Pallavi Madhiraju on May 13, 2026   Pharma & Biotech  

Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?

Novo shelved the asset, but Cellular Intelligence sees a platform test. Parkinson’s cell therapy now faces its harder commercial trial.

Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?

By Pallavi Madhiraju on May 9, 2026   Pharma & Biotech  

Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?

Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.

Why Apotex’s Apo-Semaglutide approval could reshape Canada’s diabetes drug market

By Pallavi Madhiraju on May 3, 2026   Pharma & Biotech  

Why Apotex’s Apo-Semaglutide approval could reshape Canada’s diabetes drug market

Canada has generic Ozempic momentum. Apotex’s approval turns GLP-1 access into a pricing and supply-chain test.

Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?

By Pallavi Madhiraju on April 4, 2026   Pharma & Biotech  

Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?

Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.

Novo Nordisk’s Awiqli approval could change how basal insulin is used in type 2 diabetes

By Pallavi Madhiraju on March 28, 2026   Pharma & Biotech  

Novo Nordisk’s Awiqli approval could change how basal insulin is used in type 2 diabetes

Novo Nordisk’s Awiqli wins FDA approval as the first once-weekly basal insulin. Read what this could change for type 2 diabetes care.

What the Hims & Hers Health, Inc. and Novo Nordisk collaboration reveals about the future of obesity drug commercialization

By Soujanya Ravi on March 26, 2026   Pharma & Biotech  

What the Hims & Hers Health, Inc. and Novo Nordisk collaboration reveals about the future of obesity drug commercialization

Explore how Hims & Hers and Novo Nordisk are expanding GLP-1 access and what it means for obesity care, pricing, and regulation.

C2N Diagnostics advances PrecivityTauDx programme as tangle biomarker gains Phase 3 evidence

By Pallavi Madhiraju on March 22, 2026   Medical Devices & Diagnostics  

C2N Diagnostics advances PrecivityTauDx programme as tangle biomarker gains Phase 3 evidence

C2N’s eMTBR-tau243 plasma assay shows independent prognostic value in Phase 3 Evoke data. What this means for Alzheimer’s patient selection. Read the analysis.

Novo Nordisk–Prothena coramitug program reaches key Phase 3 milestone in ATTR cardiomyopathy

By Pallavi Madhiraju on March 10, 2026   Pharma & Biotech  

Novo Nordisk–Prothena coramitug program reaches key Phase 3 milestone in ATTR cardiomyopathy

Prothena earns a $50M milestone as Novo Nordisk advances coramitug in Phase 3 for ATTR cardiomyopathy. Discover what this means for amyloid therapies.

Amazon adds oral Wegovy to pharmacy platform: Will this reshape obesity care logistics?

By Pallavi Madhiraju on January 10, 2026   Pharma & Biotech  

Amazon adds oral Wegovy to pharmacy platform: Will this reshape obesity care logistics?

Amazon Pharmacy now delivers oral Wegovy with insurance and cash-pay options. Find out how this reshapes GLP-1 access and obesity care.

1 2 Next »

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes